{
  "entity_id": "B-003289",
  "folder": "Gene-Technology-Technical-Advisory-Committee",
  "name": "Gene Technology Technical Advisory Committee",
  "type": "Statutory Body",
  "jurisdiction": "Commonwealth",
  "portfolio": "Health, Disability and Ageing",
  "website": "https://www.ogtr.gov.au/committee/gttac",
  "data_status": "partial",
  "completeness": {
    "has_strategy_brief": true,
    "has_strategy_structured": true,
    "has_vision": false,
    "has_kpi_targets": false,
    "has_kpi_results": false,
    "has_strategy_overview": true,
    "has_legislation_text": true,
    "has_legislation_structured": false,
    "has_global_initiatives_text": false,
    "has_ideas": true,
    "has_artifacts": true,
    "n_ideas": 12,
    "n_legislation": 0,
    "n_artifacts": 2,
    "n_kpi_targets": 0,
    "n_kpi_results": 0,
    "n_outcomes": 1,
    "verified_own_data": true
  },
  "strategy_profile": {
    "status": "needs_review",
    "confidence": "medium",
    "summary": "To provide scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting.",
    "official_site_url": "https://www.ogtr.gov.au/committee/gttac",
    "source_documents": [],
    "purpose": {
      "text": "To provide scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting.",
      "source_url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf",
      "source_page": 1,
      "source_deep_url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf#page=1"
    },
    "vision": null,
    "strategic_priorities": [],
    "values": [],
    "outcomes": [
      {
        "name": "Outcome 1: Advice on Genetically Modified Organisms",
        "description": "To provide scientific and technical advice on applications for the intentional release of GMOs into the environment and on the commercial supply of genetically modified organisms.",
        "activities": [
          "Reviewing and advising on licence applications for the intentional release of GMOs",
          "Reviewing and advising on Risk Assessment and Risk Management Plans (RARMPs) for GMO applications"
        ],
        "source_url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf",
        "source_page": 1,
        "source_deep_url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf#page=1"
      }
    ],
    "performance_measures": [],
    "document_alignment_terms": {
      "must_support": [
        "To provide scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting."
      ],
      "watch_terms": [],
      "avoid_claiming_without_evidence": []
    },
    "review_note": "Structured strategy exists but is incomplete."
  },
  "strategy_brief_md": "# Gene Technology Technical Advisory Committee — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Corporate Plan**: [2025-26](https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)\n\n## Our purpose / purposes\n\n> To provide scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting. [[CP p.1](https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf#page=1)]\n\n## Outcomes\n\n### Outcome 1: Advice on Genetically Modified Organisms\nTo provide scientific and technical advice on applications for the intentional release of GMOs into the environment and on the commercial supply of genetically modified organisms. [[CP p.1](https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf#page=1)]\n\n**Key activities:**\n- Reviewing and advising on licence applications for the intentional release of GMOs\n- Reviewing and advising on Risk Assessment and Risk Management Plans (RARMPs) for GMO applications",
  "strategy_overview_evidence_md": null,
  "internal_strategy_evidence_md": "# Gene Technology Technical Advisory Committee - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:08:29.365952+00:00\n**Entity ID**: B-003289\n**Entity type**: Statutory Body\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.ogtr.gov.au/committee/gttac\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 2 |\n| pages | 5 |\n\n## Executive Readout\n\n### Purpose\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n\n### Role and Functions\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n\n### Strategic Priorities\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- Prof Young is President-elect of the International Union of Microbiological\nSocieties, is a Fellow of the Australian Academy of Health and Medical\nSciences and the Queensland Academy of the Arts and Sciences and has been the President of the\nAustralian Society for Microbiology (2012-2014), the Australasian Virology Society (2001-2011) and the\nAsia-Pacific Society for Medical Virology (2012-2015).\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- Documents\nDownload\ncommunique_gttac_1_december_2025.docx as\nWord\n- 84 KB\nDownload\ncommunique_gttac_1_december_2025.pdf as\nPDF\n- 197 KB\nPublication type:\nMeeting communique\nPublication date:\nDecember 2025\nLast updated:\n9 February 2026\n  Source: `pages/publications-index.html (https://www.ogtr.gov.au/resources/publications/communique-gttac-meeting-1-december-2025)`\n- ]jJ�\u0018�<���JdG\u0012;�~o��n�=\u0002�I\u0014�9�q�@5\u0003��K����i\u0019��f�KH��\u0003w\u0002�i\n����@�.��\u000e�o�����:��=}9��l*H[�&G�WL�<�+��~�i�,�D�=���I���9�@5=���KuV�wD�A���|�t=�̼q�)��s�}i�|���\u001c��\u0018�.�s0���K�ȁܕ���V�?���f̸�#p?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n\n## KPIs, Targets, and Where They Are At\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- Prof Young is President-elect of the International Union of Microbiological\nSocieties, is a Fellow of the Australian Academy of Health and Medical\nSciences and the Queensland Academy of the Arts and Sciences and has been the President of the\nAustralian Society for Microbiology (2012-2014), the Australasian Virology Society (2001-2011) and the\nAsia-Pacific Society for Medical Virology (2012-2015).\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- Documents\nDownload\ncommunique_gttac_1_december_2025.docx as\nWord\n- 84 KB\nDownload\ncommunique_gttac_1_december_2025.pdf as\nPDF\n- 197 KB\nPublication type:\nMeeting communique\nPublication date:\nDecember 2025\nLast updated:\n9 February 2026\n  Source: `pages/publications-index.html (https://www.ogtr.gov.au/resources/publications/communique-gttac-meeting-1-december-2025)`\n- ]jJ�\u0018�<���JdG\u0012;�~o��n�=\u0002�I\u0014�9�q�@5\u0003��K����i\u0019��f�KH��\u0003w\u0002�i\n����@�.��\u000e�o�����:��=}9��l*H[�&G�WL�<�+��~�i�,�D�=���I���9�@5=���KuV�wD�A���|�t=�̼q�)��s�}i�|���\u001c��\u0018�.�s0���K�ȁܕ���V�?���f̸�#p?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- GTTAC noted the conclusion of the RARMP, that the proposed clinical trial poses negligible risks\nto the health and safety of individuals and the environment as a result of gene technology.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- [pages 1,2]\n[Page 1]\nGene Technology Technical Advisory Committee\n2026-2029\nDr Jason Smythe\nBSc (Hons), PhD, Grad.Cert.Mgmt.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- She has led international efforts to translate breast and\novarian cancer genetic data, identifying key risk variants and linking\nthem to their target protein-coding genes and noncoding RNAs to\nreveal how they drive cancer.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- [Page 8]\nGene Technology Technical Advisory Committee\n2026-2029\nDr Graham Bonnett\nDr Graham Bonnett was a research scientist with CSIRO from 1993 to 2026.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $3, $4 | ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007 | `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)` |\n| $13 million, 13 million | She has published 70 peer-reviewed papers in leading oncology\nand haematology journals and has been a Chief Investigator on grants totalling over $13 million. | `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)` |\n| $3, $4 | ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007 | `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)` |\n\n## Key Achievements\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- He completed\nundergraduate degrees (1990) and PhD (1997) at the University of Adelaide\nand followed this with postdoctoral positions at the University of Oxford\nand Imperial College, London, UK, the US National Institutes of Health,\nBethesda, MD before returning to Australia in 2003.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- Prof Young is President-elect of the International Union of Microbiological\nSocieties, is a Fellow of the Australian Academy of Health and Medical\nSciences and the Queensland Academy of the Arts and Sciences and has been the President of the\nAustralian Society for Microbiology (2012-2014), the Australasian Virology Society (2001-2011) and the\nAsia-Pacific Society for Medical Virology (2012-2015).\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- Documents\nDownload\ncommunique_gttac_1_december_2025.docx as\nWord\n- 84 KB\nDownload\ncommunique_gttac_1_december_2025.pdf as\nPDF\n- 197 KB\nPublication type:\nMeeting communique\nPublication date:\nDecember 2025\nLast updated:\n9 February 2026\n  Source: `pages/publications-index.html (https://www.ogtr.gov.au/resources/publications/communique-gttac-meeting-1-december-2025)`\n- ]jJ�\u0018�<���JdG\u0012;�~o��n�=\u0002�I\u0014�9�q�@5\u0003��K����i\u0019��f�KH��\u0003w\u0002�i\n����@�.��\u000e�o�����:��=}9��l*H[�&G�WL�<�+��~�i�,�D�=���I���9�@5=���KuV�wD�A���|�t=�̼q�)��s�}i�|���\u001c��\u0018�.�s0���K�ȁܕ���V�?���f̸�#p?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2]\n[Page 1]\nGene Technology Technical Advisory Committee\n2026-2029\nDr Jason Smythe\nBSc (Hons), PhD, Grad.Cert.Mgmt.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- Resolutions\n• The committee does not agree that the risk assessment identifies all plausible risk\nscenarios by which the proposed dealings could potentially give rise to risks relating to\nthe health and safety of people or the environment, specifically related to risk scenario 2.\n• The committee does not agree that the limits and controls proposed in the draft licence to\nprevent the spread of the GMO are appropriate for the trial, specifically related to risk\nscenario 3.\n• The committee does not agree with the overall conclusion of the RARMP.\n• The Regulator should consider clarifying licence condition wording aiming to reduce\nfaecal-oral contact/transmission.\n• The Regulator should consider whether the uncertainty in the pre-clinical data is\nsufficient to support that the likelihood of transmission of the ttr operon to pathogenic\nbacteria is negligible or low.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- [Page 2]\nResolutions\n• The committee agrees that the risk assessment identified all plausible risk scenarios by\nwhich the proposed dealings could potentially give rise to risks relating to the health and\nsafety of people or the environment.\n• The committee agrees with the overall conclusions of the RARMP.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- Prof Young is President-elect of the International Union of Microbiological\nSocieties, is a Fellow of the Australian Academy of Health and Medical\nSciences and the Queensland Academy of the Arts and Sciences and has been the President of the\nAustralian Society for Microbiology (2012-2014), the Australasian Virology Society (2001-2011) and the\nAsia-Pacific Society for Medical Virology (2012-2015).\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n- They must also consult on Risk Assessment and Risk Management Plans (RARMPs) prepared for all DIR licence applications.\n  Source: `pages/homepage.html (https://www.ogtr.gov.au/committee/gttac)`\n- Members include experts in relevant scientific fields (such as risk assessment, public health and ecology) and a layperson.\n  Source: `pages/homepage.html (https://www.ogtr.gov.au/committee/gttac)`\n- Documents\nDownload\ncommunique_gttac_1_december_2025.docx as\nWord\n- 84 KB\nDownload\ncommunique_gttac_1_december_2025.pdf as\nPDF\n- 197 KB\nPublication type:\nMeeting communique\nPublication date:\nDecember 2025\nLast updated:\n9 February 2026\n  Source: `pages/publications-index.html (https://www.ogtr.gov.au/resources/publications/communique-gttac-meeting-1-december-2025)`\n- ]jJ�\u0018�<���JdG\u0012;�~o��n�=\u0002�I\u0014�9�q�@5\u0003��K����i\u0019��f�KH��\u0003w\u0002�i\n����@�.��\u000e�o�����:��=}9��l*H[�&G�WL�<�+��~�i�,�D�=���I���9�@5=���KuV�wD�A���|�t=�̼q�)��s�}i�|���\u001c��\u0018�.�s0���K�ȁܕ���V�?���f̸�#p?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n\n## Corporate Values and Operating Culture\n\n- All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022\n  Source: `pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)`\n- ��Yb&��\u0003�NK\u0002�����\b�\u0010�\u000f�G\u001e\b��*\u001e\u0003U\u001a&��6F��!s߄\u0007b/\u001bH��q��\u0011�\u001ac�p����\u0018�&K�#A�A'2^\u0014^��\u0003��β!�\u0003h\u001c7�`�&<���`\u001f@+��\u0006ȽP����� \u0003\u0019�'��N\u0019�<��4\"*:�5~{��v�P8ˣ�d�[�\f��h���U�0{FW�#��t�s�2�*�J&����'\u0006*�]Kk�;�Aj-��6[��vLOѴ\"��b�_�)��w����T\n\u0016S����1���\u0001�\u000bu���[g}��g��\u00148�����;�2���\"O��I���Vk���2���\u0012�����`)�+oA\f��{\u001d�z�\f�aT,�ѢS�\u001f������ѴzW��s�c\u001bFS���d/ňհ�6'*�^*�k��`�@��\u0002��6���\u0013>\u0004\u00114oE��\u001a�I�^�\f�)\u0010�/Oi�=C\fz�l���Zgf����Mu����F�2��b�`ǖ�6�:�yߠ�k\u001b��T]k�8]�57�f���Syܷej��pg\u001aZ��2\u001a��O�{snV� \u001f\u000e�w����:�\u0005\u001f�����D��\n��|\\O�\u001d�m��\u0014I�\u0002#�\u001c�^�\u000eͥ]�b�S0z����!\u000e�[\u001eR��J]_�z�?�@SiO���V�z'W�\\�\u0001\u0005��Wv�FQ\"�;\u0010V\n�&��^��ܠ�W��Ug�[bi�^��\u00039T4Z���8!:���Tg*�I3LF`�\u001e�.h\\�Q1-\u0004a��o^E�]�Qe}]�Q\"�=�L��S��4٘<{/;�Ać����`2�E>��ZM\u0001-�7̯s\u0005��RE\u0015�G\u000e�}��\u001d���z\u001aPO�����1\u001f���}h@\u001f�j����Y�i��C��s�\u0017\u0001\u0016�;Z��\u0019���ZOHPC\u0019SU��(e&���9�\"�,\\\u000esZ¬���1D���\n�P\u000b�\u0013��\u0016�f��\u001c\u001e�` ��!��ƒ���_ʸ�\"�\u001a��\u0001\b�h�XW�\u001fo�'��n\u0001�- q��q��.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- ��\u0011\b\u0002W\u0001�\u0003\u0001\"\u0002\u0011\u0001\u0003\u0011\u0001��\u001f\u0001\u0005\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0010\u0002\u0001\u0003\u0003\u0002\u0004\u0003\u0005\u0005\u0004\u0004\u0001}\u0001\u0002\u0003\u0004\u0011\u0005\u0012!1A\u0006\u0013Qa\u0007\"q\u00142���\b#B��\u0015R��$3br� \n\u0016\u0017\u0018\u0019\u001a%&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz���������������������������������������������������������������������������\u001f\u0001\u0003\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0001\u0002\u0003\u0004\u0005\u0006\u0007\b \n\u000b���\u0011\u0002\u0001\u0002\u0004\u0004\u0003\u0004\u0007\u0005\u0004\u0004\u0001\u0002w\u0001\u0002\u0003\u0011\u0004\u0005!1\u0006\u0012AQ\u0007aq\u0013\"2�\b\u0014B���� #3R�\u0015br�\n\u0016$4�%�\u0017\u0018\u0019\u001a&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������\f\u0003\u0001\u0002\u0011\u0003\u0011?�2��^�=M>58�O>ԛH}ۉ\u0007ڜ��r�t���Ϡ��S \u001f&��;T�=jF*�!ɦ# O'�ph`\"��F\u0013�jV�y��3ғ{�\n{\u000e\u000e)Xs�}M\u0016\u001a�\u0002�v1�1J�B�\u0007\u001d�&�$o^s����%J�}(i��\u001b�7\b�9��[\n��h\u00013��\u000fzw�\u001a�3Ҙ�@�t�@��;w)�Ҝ�-�p\u0019�J�\u0002�R3ޕƵ!�\u000e\u0001=\u000f57�w\n�*0�<z��I�\u0012��K[�\u001a�H?t\u001e�q@\nŁ�jP�.T{\u001aB�\u001c:�~i�v5Fp�q�OR7\u0012�\u001dq�)���#�\u0014�Q@�d���C}�!���qޑ�1�q�J\u0018�ܷN��\u001b�\u000fj,-`�H\ng��0)B`\u00058�9���>�,\f\u0003LpN =����>v�4\u0005��\u0004���`�\u001a�|��}3Me\u0003��\u00150\b�r��i0���>���1\f�s�����Q��\u001eؤUU`\u00158'�i'\u001b�\u0002��CF��1���\u0003��\u001cШќ���81-�\u0006\u0001�H C�/�R\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- \u0011��#\u0012�9�4֚�\u0018ԀU�3R\u0004���l�\u0015��m�}sJ�\u0004�,ж\u0002�䓃�NO3\u0001U8\u0003��N\" @��=iCr\u0001�E�d5<�9a�3J\\��&1�S�q�W8�*�峌v�1�\n�$\u001001O*�U�\u001e�\u0005�\b�y�,h\u001c�N0)�h:6`����FT|�c����\"�\u001fϵ Lr�'��j\u000bA$m�US��*�c8=iA\u000b��V\u000eN�p}�\u000b@C'V�wg�S^_�S���I�c.�\u0004�g\u001a��\u0016�;d0\f� \u000e�!\u0019NF\b�0s��\u0013�\u0011|�\u001d�clh:����^��-���=\u001e��{W�u5\f,d\u0012ô\u0010W\b��7?'����\u0006u[�v*6r����&��&�\u0016��tK}=\u0011����*\u000f$���\u0019\u0019\u0007ub������}6v\u0011���<�\u000e��PN�x\u0001A�`�Iε����ާs,�}��4��9\u0018�Wv��\u0018�\u0003nX�s�\u00064S�v���/��#\")nm���\u000e�\u0014h�F\u000e8g|��p<���\f�ӴOF��z\u001d����P׭m�K�d�;�\"Xb\u001b�a� q���8\u0019�ܝ���\u000f��ĭl.m`��X�DT]��G\u0005F\u0006v����\f:�s����~��1\u0016�n��!�\u0004\nG���!UI%��_�ŕyʖ\u0005���_\u000f�IՄR�y��#=��\u001b\"'�F\u0003��6H;�!6�o��c���ynZ������;?�?\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u0015\u000f\u0006��m\u001f��5���oS��s=�C�\u001e���}+NW-݉nڜ%��A�]\n[k�Yu\b�0��\u0001�d�Ϗ�}Iz\u001a��\nZ�ZYx�L�E{�}r;�\u0015C\u0015L�*�r\u0002���\u001fC�&��ew\u0016\u001a�m\u0014�\u0012���;}k�����Gԥ�<A��\u0012\u001dB�\u0014\u0017(��&p?�8 q��\"��I��ѽ<JN�<�\u000b��\u0011�8*Pm�NBa@\n����y8f�EfV22��p�\"�۸\u0013�Ӗ\u001d�x����[6�}\u0017�``'G尣'��z�:REv�]˱X����\u0019,�z��q�^�\u0012��j�a��\u0002��\u00125d܄\u0010�:�>a�ߏSګی�n�\u0004*�t'�B\u0001</a�\u0007`U�[�rc�o�0�\"W=pĞ����Vu6�v�0�#\n\u0018��lc�r^z��=�L|�p�v��H�\u0019X\"\u0006 ��`�G�\u001dI��_-��_\u00045[ ��axvŚ��KJ �\u00014\u0001��8<��\u0007P8��_UZK�#���ԓϮxǸ\u001f�N�V_�|;\u0016���S�\u0019�#\u0018��Ve*�qӹ�{W6#\u000f\fU\u0007N}M��煬�\u0013�_\f�����)\u0019��e�\u0015�m�FZO.�d�I,O+�Y_���=K�'���zU��J��e�J�\u0010NI�\u0003��_L�W-�x��I�\u0012��6�\u0003g��~q��T�Uq��\u001e\u0013\u001bO\u0013IIu;�5aq�(F�\u0007��Aʹ\u0013�+���\u0002�����}�`�F0:ը��'\u000b���\u001b�+�ph�s��ӷ(�\u000f���<ᛟµ-�\u0004�\b��\u0007Pǽs�8�\u000e�l �:⡹�w��8a�9�~�3���(��x�#�U����6�]鸗�N��\u001a�o\u0017(d���\u0006�\u001dS\u0012�\u0012F\u0006x4��z���[�����\u001dG;�z\u0017��k�\u0015j���-�Zhc�찺����' g\u0003#��׀|_��g���WZ��\f��3F\u000b\u0010\u0004�����.4_��\u0019�S��.&���1F\f�(��\b'%�'�͊��\u0015��b�ytZz����G-\u001ff���oj�6\u0011�L�,U�\u0015V~\u00079Q��#�s�z��B_`���{��֝u\u001f�\u00024K�\u0013i@�3�F;w���.�j.\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- �\u001fx�N�g\u001d?n\n!YG�O���*8ќd!,\u0018�~��@Y�\u001bD�F\u0007\u0018۷����>�\" h�cn3�\u000fA�?�ұe@�|��:���ҔN\n\u00103��}��\b��\u0014^㒲$\u0010,��[@l����x��'�W��8�kZ[�\u0018\u001c�\u001c\nB�\u001f�!6�\u0017��\u0004c����_\u0007Z���i\u0007��fp�\u0015w`'���\nO�_QxT��6q�����\u001a#Cu���\u00190���\u0005+�I�\\/qh�-\u0017W��\u0013n��O��Np�� ��Wf��H\u001bq������B��<aa��y��I\u0012W�d��y��\u0001\u0019H\u001c�\nLy.\bm�F\u0006H�\u0005��%������[\u0017\u0017\u0012�$�$�U\u0019�*��\u001c�Q�T\u0002\n\u0003RX��X�l�e���e�o>�\u0018T�5*|����BC��s� \u0006��=M\u001bMY\u0016�O\u000e�x�Xi�\u001c����{�brҘ����)�\f�\u0014�p�\u000e��Ha�S���o\u000b��s�\\�o�\u001aV��R�ga�<�>��B\u0019�|�P1��x�ƞ\u0018֮�u�j��I��ݟM��D�\\N���DDr\u0004�dI7�\u0004�\\c96d{�Ӡ{�Im�m��g�o�$\u0019\u001b1H6y�\u0001�H�\u0011�\u000f�\u0005+4-nq�!�q�:[Y��N�ͥ�\u0014v��(V\u0018I\u0005Y6�����v�\u0004�hZ��\u0007�$�]�$V\"7�Xc���XT�\"d��4�����\u001c��2�^�͞(l�\u0005���ntٳ\u0019%ͺ��8\n�-��\u0004��I.\u0006r-ZC���i�\u001f�t�o�I\u001aZ�\u0019�<s��TX�\u0018\u001f}2�>s���NZ$Άi��:]��no#�N�x4�e��%��A\u0006i����T�0\u001f�`�w\n��ӵ(�\u001fN�Ǌo\u0005爯[xӒ̇��>dM�\u0015\u000e�G,��\u0002=`�GQ���Y�ὐ�^���7qH�u\u0003l�r��\u0016X���qۗ�3e�{H�|+�&y�a\u0005��!ee�\u0012��ă�*2G��D��M\u0015���5�\u001c|@ht�K+�>���f��.1�\u0004{�x\u001c�c�y\u0018\"��}\")O��\u001d\u0018�u&g�\b~ʠ���G�2\u001c\u0010@`\f`��+��wU��č>�\u001dCH�A��ܲJd0�@Tɘ�\u0017\b['�d\f1�\n\u0002��\u0013�\n  Source: `pages/taskforces-index.html (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx)`\n- [pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)`\n- He was founding Head of the Gene Therapy Research Unit at the Children's Medical Research Institute, has\npublished over 30 research manuscripts and numerous professional reports, been granted 5 patents and\nawarded 4 International Research Fellowships.\n  Source: `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py <entity>` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `pages/about.html` - pages - https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe\n- `pages/contact.html` - pages - https://www.ogtr.gov.au/request-accessible-format?destination=/resources/collections/information-institutional-biosafety-committees\n- `pages/homepage.html` - pages - https://www.ogtr.gov.au/committee/gttac\n- `pages/publications-index.html` - pages - https://www.ogtr.gov.au/resources/publications/communique-gttac-meeting-1-december-2025\n- `pages/taskforces-index.html` - pages - https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.docx\n- `other-pdfs/communique_gttac_1_december_2025.pdf` - other-pdfs - https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf\n- `other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf` - other-pdfs - https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.",
  "legislation_md": "# Gene Technology Technical Advisory Committee - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:02:53.412363+00:00\n**Entity ID**: B-003289\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 7\n- Unique legislation references found: 2\n\n| Type | Count |\n|---|---:|\n| Act | 1 |\n| Regulation | 1 |\n\n## Legislation References\n\n### Gene Technology Act 2000\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=Gene+Technology+Act+2000\n\n**Sources**:\n- `pages/about.html`\n- `pages/homepage.html`\n- `other-pdfs/communique_gttac_1_december_2025.pages.jsonl`\n\n**Evidence contexts**:\n- uestion or provide general feedback\nsubscribe to updates about new applications, consultations, issued licences and legislative changes\nprovide feedback about this website\nlet us know if you think someone is not complying with their responsibilities under the\nGene Technology Act 2000\n.\nOGTR general enquiries\nContact details for general enquiries, including asking us questions, giving us feedback or making a complaint.\nEnquiries\nogtr@health.gov.au\nFree call\n1800 181 030\nFreedom of Information (FOI) coordinator\nContact the FOI coordinator f\n  Source: `pages/about.html`\n- es scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting.\nGTTAC provides advice on:\ngene technology, genetically modified organisms (GMOs) and genetically modified (GM) products\napplications made under the\nGene Technology Act 2000\nthe biosafety aspects of gene technology\nprinciples, guidelines and codes of practice for GMOs and GM products.\nThe Regulator must consult the committee on all licence applications for dealings involving intentional release of GMOs into the environment (DIR)\n  Source: `pages/homepage.html`\n- uniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.\nThe Regulator seeks advice from GTTAC on licence applications to work with Genetically Modified\nOrganisms (GMOs)\n  Source: `other-pdfs/communique_gttac_1_december_2025.pages.jsonl`\n\n### Gene Technology Regulations 2001\n\n**Type**: Regulation\n**Confidence**: medium\n**Mentions**: 2\n**Register search**: https://www.legislation.gov.au/search?query=Gene+Technology+Regulations+2001\n\n**Sources**:\n- `pages/homepage.html`\n- `other-pdfs/communique_gttac_1_december_2025.pages.jsonl`\n\n**Evidence contexts**:\n- pplications for dealings involving intentional release of GMOs into the environment (DIR) not assessed as a limited and controlled release. They must also consult on Risk Assessment and Risk Management Plans (RARMPs) prepared for all DIR licence applications.\nThe Gene Technology Regulations 2001 details how the committee should make decisions, its reporting requirements and procedures for convening meetings.\nMembers of GTTAC\nThe committee has 20 members appointed by the Minister. Members include experts in relevant scientific fields (such as risk ass\n  Source: `pages/homepage.html`\n- ically Modified\nOrganisms (GMOs) and on Risk Assessment and Risk Management Plans (RARMPs) prepared for\napplications. The purpose of this Communiqué is to provide a brief overview of GTTAC’s\nconsideration of applications and RARMPs and, in accordance with the Gene Technology\nRegulations 2001, to publish committee resolutions given to the Regulator. The Communiqué also\nprovides an overview of any other deliberations of the committee. It does not include information\nthat is treated as Confidential Commercial Information in accordance with the Act.\n  Source: `other-pdfs/communique_gttac_1_december_2025.pages.jsonl`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/contact.html` (page)\n- `pages/homepage.html` (page)\n- `pages/publications-index.html` (page)\n- `pages/taskforces-index.html` (page)\n- `other-pdfs/communique_gttac_1_december_2025.pages.jsonl` (pdf_pages)\n- `other-pdfs/gene-technology-technical-advisory-committee-gttac.pages.jsonl` (pdf_pages)",
  "global_initiatives_md": null,
  "strategy": {
    "reporting_period": "2024-25",
    "corporate_plan_period": "2025-26",
    "vision": null,
    "vision_source_page": null,
    "purposes": "To provide scientific and technical advice to the Gene Technology Regulator and the Gene Technology Ministers’ Meeting.",
    "purposes_source_page": 1,
    "how_we_deliver": null,
    "how_we_deliver_source_page": null,
    "government_priorities": [],
    "outcomes": [
      {
        "name": "Outcome 1: Advice on Genetically Modified Organisms",
        "description": "To provide scientific and technical advice on applications for the intentional release of GMOs into the environment and on the commercial supply of genetically modified organisms.",
        "key_activities": [
          "Reviewing and advising on licence applications for the intentional release of GMOs",
          "Reviewing and advising on Risk Assessment and Risk Management Plans (RARMPs) for GMO applications"
        ],
        "source_page": 1
      }
    ],
    "values": [],
    "values_framework_name": null,
    "kpi_targets_2025_26": [],
    "kpi_results_2024_25": [],
    "_source_urls": {
      "annual_report_url": "",
      "corporate_plan_url": ""
    }
  },
  "ideas": [
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Regulation & Policy",
      "scale": "small",
      "title": "Regulatory burden scan for forms, guidance, and reporting",
      "idea": "Identify the top 10 highest-friction reporting obligations and simplify guidance, forms, or evidence requirements.",
      "quote": "All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Regulation & Policy",
      "scale": "large",
      "title": "Adaptive regulation program with live feedback loops",
      "idea": "Create an adaptive regulation model using sandboxes, industry data, risk scoring, and regular rule updates.",
      "quote": "All requests\nogtr@health.gov.au\nEnquiries\n1800 181 030\nOGTR applications\nContact details for asking about, getting help with and submitting applications for licences, certification and accreditation.\nogtr.applications@health.gov.au\n1800 181 030\nMonitoring and Compliance Section\nContact the Monitoring and Compliance Section for guidance and advice about ongoing compliance requirements.\nogtr.m&c@health.gov.au\n1800 181 030\nLast updated:\n28 February 2022",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Regulated entities / policy teams",
      "source": "pages/about.html (https://www.ogtr.gov.au/about-ogtr/contact-and-subscribe)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Risk & Assurance",
      "scale": "small",
      "title": "Recommendation tracker for audits, reviews, and inquiries",
      "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.",
      "quote": "Resolutions\n• The committee does not agree that the risk assessment identifies all plausible risk\nscenarios by which the proposed dealings could potentially give rise to risks relating to\nthe health and safety of people or the environment, specifically related to risk scenario 2.\n• The committee does not agree that the limits and controls proposed in the draft licence to\nprevent the spread of the GMO are appropriate for the trial, specifically related to risk\nscenario 3.\n• The committee does not agree with the overall conclusion of the RARMP.\n• The Regulator should consider clarifying licence condition wording aiming to reduce\nfaecal-oral contact/transmission.\n• The Regulator should consider whether the uncertainty in the pre-clinical data is\nsufficient to support that the likelihood of transmission of the ttr operon to pathogenic\nbacteria is negligible or low.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Risk & Assurance",
      "scale": "large",
      "title": "Integrated assurance and lessons-learned system",
      "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.",
      "quote": "Resolutions\n• The committee does not agree that the risk assessment identifies all plausible risk\nscenarios by which the proposed dealings could potentially give rise to risks relating to\nthe health and safety of people or the environment, specifically related to risk scenario 2.\n• The committee does not agree that the limits and controls proposed in the draft licence to\nprevent the spread of the GMO are appropriate for the trial, specifically related to risk\nscenario 3.\n• The committee does not agree with the overall conclusion of the RARMP.\n• The Regulator should consider clarifying licence condition wording aiming to reduce\nfaecal-oral contact/transmission.\n• The Regulator should consider whether the uncertainty in the pre-clinical data is\nsufficient to support that the likelihood of transmission of the ttr operon to pathogenic\nbacteria is negligible or low.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / assurance teams",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Regulatory capture",
        "Over-automation of judgement"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Case Processing",
      "scale": "small",
      "title": "Triage queue for stuck or ageing cases",
      "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.",
      "quote": "The Regulator seeks advice from GTTAC on licence applications to work with Genetically Modified\nOrganisms (GMOs) and on Risk Assessment and Risk Management Plans (RARMPs) prepared for\napplications.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Case Processing",
      "scale": "large",
      "title": "End-to-end case processing redesign",
      "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.",
      "quote": "The Regulator seeks advice from GTTAC on licence applications to work with Genetically Modified\nOrganisms (GMOs) and on Risk Assessment and Risk Management Plans (RARMPs) prepared for\napplications.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Applicants / case officers",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Staff Productivity",
      "scale": "small",
      "title": "Reusable briefing and summary assistant for internal documents",
      "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.",
      "quote": "[pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Staff Productivity",
      "scale": "large",
      "title": "Department-wide knowledge and briefing platform",
      "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.",
      "quote": "[pages 1,2,3]\n[Page 1]\nGene Technology Technical Advisory Committee\n1 December 2025\nCommuniqué\nThis Communiqué covers matters considered at the 47th videoconference of the\nGene Technology Technical Advisory Committee (1 December 2025)\nThe Gene Technology Technical Advisory Committee (GTTAC) is a statutory advisory committee\nestablished under the Gene Technology Act 2000 (the Act) to provide scientific and technical\nadvice to the Gene Technology Regulator (the Regulator) and the Gene Technology Ministers’\nMeeting.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "APS staff / executives",
      "source": "other-pdfs/communique_gttac_1_december_2025.pdf (https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Sensitive information leakage",
        "Inconsistent quality of generated drafts"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Citizen Participation",
      "scale": "small",
      "title": "Consultation feedback summaries with response tracking",
      "idea": "Summarise consultation submissions by theme and publish what changed in response.",
      "quote": "She has contributed to many gene technology reviews, and as Co-Chair\nof the Australia and New Zealand Legal and Regulatory Affairs Committee of the International Society Cell\nand Gene Therapy from 2014 to May 2026, and as a cross-member from the Gene Technology Technical\nAdvisory Committee to the Gene Technology Ethics and Community Consultative Committee from 2015 to\n2025.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Citizen Participation",
      "scale": "large",
      "title": "Always-on policy participation platform",
      "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.",
      "quote": "She has contributed to many gene technology reviews, and as Co-Chair\nof the Australia and New Zealand Legal and Regulatory Affairs Committee of the International Society Cell\nand Gene Therapy from 2014 to May 2026, and as a cross-member from the Gene Technology Technical\nAdvisory Committee to the Gene Technology Ethics and Community Consultative Committee from 2015 to\n2025.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Citizens / stakeholders / policy teams",
      "source": "other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability",
        "Digital exclusion",
        "Low public trust if feedback is not acted on"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Data & Performance",
      "scale": "small",
      "title": "KPI evidence register with named owners",
      "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.",
      "quote": "She has led international efforts to translate breast and\novarian cancer genetic data, identifying key risk variants and linking\nthem to their target protein-coding genes and noncoding RNAs to\nreveal how they drive cancer.",
      "impact": "High",
      "effort": "Low",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)",
      "implementation": [
        "Pick one high-volume process or document family.",
        "Name an owner and baseline current volume, time, cost, and satisfaction.",
        "Run a 4-8 week pilot with clear before/after metrics.",
        "Publish lessons and decide whether to scale."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    },
    {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "category": "Data & Performance",
      "scale": "large",
      "title": "Outcome dashboard linking budget, delivery, and public impact",
      "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.",
      "quote": "She has led international efforts to translate breast and\novarian cancer genetic data, identifying key risk variants and linking\nthem to their target protein-coding genes and noncoding RNAs to\nreveal how they drive cancer.",
      "impact": "Very High",
      "effort": "High",
      "proof": "Evidence-backed",
      "beneficiaries": "Executives / Parliament / public",
      "source": "other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf (https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf)",
      "implementation": [
        "Create a senior responsible owner and cross-functional delivery team.",
        "Map legislation, data, privacy, procurement, cyber, and workforce constraints.",
        "Co-design with users and frontline staff before technology selection.",
        "Stage delivery through pilots, benefits tracking, and public reporting."
      ],
      "risks": [
        "Privacy and data quality",
        "Change fatigue",
        "Unclear accountability"
      ]
    }
  ],
  "legislation_administered": [],
  "artifacts": [
    {
      "category": "other-pdfs",
      "year": "2026",
      "url": "https://www.ogtr.gov.au/sites/default/files/2026-03/gene-technology-technical-advisory-committee-gttac.pdf",
      "file": "other-pdfs/gene-technology-technical-advisory-committee-gttac.pdf",
      "bytes": 1221491,
      "link_text": "Download [Committee or Group] Gene Technology Technical Advisory Committee (GTTAC) (PDF) as PDF - 2 MB"
    },
    {
      "category": "other-pdfs",
      "year": "2026",
      "url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf",
      "file": "other-pdfs/communique_gttac_1_december_2025.pdf",
      "bytes": 201279,
      "link_text": "Download communique_gttac_1_december_2025.pdf as PDF - 197 KB"
    }
  ],
  "_meta": {
    "snapshot_built_at": "2026-05-13T11:02:50+00:00",
    "strategy_brief_meta": {
      "model": "nova-micro",
      "folder": "Gene-Technology-Technical-Advisory-Committee",
      "annual_report": {
        "file": null,
        "url": "",
        "year": null
      },
      "corporate_plan": {
        "file": "other-pdfs\\communique_gttac_1_december_2025.txt",
        "url": "https://www.ogtr.gov.au/sites/default/files/2026-02/communique_gttac_1_december_2025.pdf",
        "year": "communique_gttac_1_december_2025"
      },
      "usage": {
        "input_tokens": 2519,
        "output_tokens": 287,
        "total_tokens": 2806,
        "model": "nova-micro"
      },
      "cost_usd": 0.000128345,
      "elapsed_seconds": 15.98,
      "generated_at": "2026-05-13T05:16:57+00:00"
    },
    "ideas_manifest": {
      "entity_id": "B-003289",
      "entity_name": "Gene Technology Technical Advisory Committee",
      "folder_name": "Gene-Technology-Technical-Advisory-Committee",
      "generated_at": "2026-05-09T23:05:19.753581+00:00",
      "idea_count": 12,
      "markdown": "ideas/Gene-Technology-Technical-Advisory-Committee_ideas.md",
      "jsonl": "ideas/ideas.jsonl",
      "inputs": [
        "Gene-Technology-Technical-Advisory-Committee_strategy-overview.md",
        "strategy-evidence.json",
        "global-intelligence/source-manifest.json"
      ]
    },
    "global_intel_meta": null
  }
}